Dopamine transporter changes after unilateral deep brain stimulation in progressive Parkinson's disease: a case report
Received 26 December 2013
Accepted for publication 11 February 2014
Published 8 April 2014 Volume 2014:10 Pages 607—611
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Huiwei Zhang,1,* Yuanyuan Wang,1,* Jinchuan Liang,2 Stefan Förster,3 Ping Wu,1 Jun Zhao,1 Yihui Guan,1 Chuantao Zuo1
1PET Center, Huashan Hospital, Fudan University, 2Department of Neurosurgery, Changhai Hospital, Shanghai, People's Republic of China; 3Department of Nuclear Medicine and TUM-Neuroimaging Center, Technical University Munich, Munich, Germany
*These authors contributed equally to this work
Abstract: Deep brain stimulation (DBS) at the subthalamic nucleus has been approved as an effective treatment for refractory symptoms of Parkinson's disease (PD). Studies have shown that bilateral DBS surgery in PD patients results in clinical improvement without reducing dopamine transporter function. Here, we report our longitudinal findings in one PD patient, ie, decreases in striatal dopamine transporter binding during one year of follow-up after unilateral DBS at the subthalamic nucleus. Based on this case, we hypothesize that clinical benefit after unilateral DBS may be not directly associated with changes in function at the subthalamic nucleus.
Keywords: deep brain stimulation, Parkinson's disease, dopamine transporter, positron emission tomography
Deep brain stimulation (DBS) has been approved as an effective treatment for refractory symptoms of Parkinson’s disease (PD). It has been shown that DBS has clinical benefit for PD patients and may reduce the need for anti-parkinsonian medication. Studies have shown that bilateral DBS surgery in PD patients results in clinical improvement without reducing dopamine depletion.1–3 Most of these studies have used 123ioflupane single-photon emission computed tomography (123I- FP-CIT SPECT) with its relatively low spatial resolution to investigate distribution of the dopamine transporter in the subregions of the basal ganglia. It is noteworthy that conclusions regarding the changes in dopamine transporter distribution have not been directly evidence-based, nor relied on direct comparison of decreases in the dopamine transporter between DBS patients, levodopa-responsive PD patients with advanced PD, or natural decline. Until now, no clinical 11C-2β-carbomethoxy-3β-(4-fluorophenyl)tropane positron emission tomography (11C-CFT PET) study has been reported focusing on comparison of dopamine degeneration in each cerebral hemisphere after unilateral DBS to the subthalamic nucleus. We report the longitudinal findings for one such PD patient, with observation of decreases in the striatal dopamine transporter ratio during one year of follow-up after unilateral DBS to the subthalamic nucleus.
A 56-year-old right-handed female PD patient with no family history of PD developed early symptoms of rigidity and mild tremor on the right side in 1995. She accepted left pallidotomy in 1999. After the surgery, pharmacological therapy was started using sustained-release carbidopa-levodopa, adamantanamine, and benzhexol hydrochloride to control her symptoms. By February 2011, her medication was proving ineffective, so the surgeons accepted her as a candidate for DBS to the subthalamic nucleus. In 2011, the motor symptoms in her left limbs were more severe than in the right limb. Her Unified Parkinson’s Disease Rating Scale (UPDRS) score was 19 in the left limb and 11 in the right. After considering the financial circumstances of her family, the surgeons chose to treat the right subthalamic nucleus.
In February 2011, 11C-CFT PET was performed after 12 hours off medication to observe dopamine transporter distribution. On the following day, the patient underwent unilateral DBS surgery to the right subthalamic nucleus. In January 2012, a follow-up 11C-CFT PET scan was performed in the “electrodes on” state after 12 hours off medication to assess the longitudinal effect of DBS on the subthalamic nucleus. The patient’s UPDRS and Hoehn and Yahr scores were assessed by the same neurologist on each occasion. The protocol used was approved by the ethics committee at Huashan Hospital, Fudan University, Shanghai, and all examinations were performed with the patient’s informed consent.
Materials and methods
The patient stopped taking anti-parkinsonian medications at least 12 hours before PET scanning. A 370 MBq injection of 11C-CFT was administered intravenously. A 20-minute three-dimensional emission scan (Biograph™ 64 HD, Siemens Healthcare, Erlangen, Germany) was acquired 60 minutes post-injection. Attenuation correction was performed using X-ray computed tomography (CT) prior to the emission scan. Following corrections for scatter, dead time, and random coincidences, PET images were reconstructed using three-dimensional filtered back projection.
Anatomically-based volumes of interest for the caudate, anterior putamen, posterior putamen, and occipital cortex were placed manually on the mean image summed over central slices encompassing the striatal structures; these volumes of interest were confirmed for the subject with reference to magnetic resonance images. From the 11C-CFT PET scan, we calculated the ratio of specific to nonspecific activity in the caudate, anterior putamen, and posterior putamen volumes of interest by subtracting parieto-occipital activity from striatal activity and dividing by parieto-occipital activity.4
Clinically, DBS had a beneficial effect on the patient’s motor symptoms according to her UPDRS and Hoehn and Yahr scores. Her total UPDRS score decreased from 46 to 24 and her Hoehn and Yahr score decreased from 4 to 2. UPDRS decreased from 11 to 8 on the right and from 19 to 6 on the left, indicating more improvement in motor symptoms in the left limbs than in the right limbs.
At baseline, 11C-CFT PET showed asymmetrically reduced dopamine transporter binding in the caudate nucleus, and in the anterior and posterior putamen bilaterally (Figure 1). One year after DBS, 11C-CFT PET showed further decreases in dopamine transporter binding in the caudate nucleus, and in the anterior and posterior putamen bilaterally. On the stimulated side, the dopamine transporter slope rate was −0.12, −0.07 and −0.16 for the anterior putamen, posterior putamen, and caudate, respectively; the annual decrease in dopamine transporter at these sites was 12%, 7%, and 16%, respectively, while on the unstimulated side, the respective dopamine transporter slope rate was −0.16, −0.08, and −0.13, respectively, with an annual decrease in dopamine transporter of 16%, 8%, and 13% (Figure 2). The slope rate was quite close between the stimulated and unstimulated sides in the three regions, suggesting that degeneration of the dopamine transporter was similar on both sides during the course of one year.
As reported previously, an 11.2% natural decline of dopaminergic neurons in advanced PD may be expected.5 Our patient’s annual decline of dopamine transporter distribution on the stimulated side was 7%–16%, and was almost equal to the 8%–16% decline found on the unstimulated side, suggesting that DBS to the subthalamic nucleus may not change dopamine transporter distribution. Hesse et al used 123I-FP-CIT SPECT to measure dopamine transporter availability and demonstrated that there was no change in striatal 123I-FP-CIT binding between pre-DBS and follow-up at one year after DBS.3 123I-FP-CIT binding was also found to be reduced to an equal extent in patients who have undergone stimulation of the subthalamic nucleus and nonoperated PD patients with advanced disease.2 In 18F-fluorodopa PET studies of presynaptic tracer binding, one demonstrated that the decline in presynaptic dopaminergic function continued in advanced PD patients despite clinically effective bilateral subthalamic nucleus stimulation,1 but another could not detect any significant difference between stimulation on and off states.6 Consequently, these studies concluded that DBS leading to clinical benefit was not associated with dopamine transporter recovery.
In our case, motor symptom improvement in the right side was not as good as on the left, indicating that DBS to the right subthalamic nucleus have an effect on motor symptoms which was not consistent with the change in dopamine transporter. Therefore, we conclude that clinical benefit after unilateral deep brain stimulation may not be directly associated with dopamine transporter function. Further studies with larger sample sizes are needed to confirm our hypothesis.
This research was supported by the National Natural Science Foundation of China (grant 81171189).
The authors report no conflicts of interest in this work.
Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry. 2005;76(9):1217–1221.
Lokkegaard A, Werdelin LM, Regeur L, et al. Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2007;34(4):508–516.
Hesse S, Strecker K, Winkler D, et al. Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson’s disease within one-year follow-up. J Neurol. 2008;255(7):1059–1066.
Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease. J Neurosci. 2010;30(3):1049–1056.
Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology. 2001;57(11):2089–2094.
Arai N, Yokochi F, Ohnishi T, et al. Mechanisms of unilateral STN-DBS in patients with Parkinson’s disease: a PET study. J Neurol. 2008;255(8):1236–1243.
18Fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging.
18F-FDG PET scans were performed 3 hours after a 11C-2β-carbomethoxy-3β-(4-fluorophenyl)tropane (11C-CFT) PET scan. The patients were fasted overnight and in the “medication off” and “DBS on” state. A 185 MBq injection of 18F-FDG was administered intravenously under standardized conditions (in a quiet, dimly lit room with the patient’s eyes open and head immobilized using a head-holder). A 10-minute three-dimensional emission scan was acquired 45 minutes post-injection. The 18F-FDG PET scan used the same three-dimensional filtered back projection reconstruction and the same PET scanner as used for 11C-CFT PET.
Twelve age-matched healthy female controls were carefully chosen for comparison of their scans with the baseline and second scans of the case patient. The PET images were analyzed using SPM2 software (Wellcome Department of Cognitive Neurology, London, UK) running on Matlab version 2006a (Mathworks Inc., Sherborn, MA, USA). These comparisons were based on a two-tailed unpaired t-test and restricted a priori to a volume of interest which included the putamen, caudate nucleus, thalamus, and the cerebellum. This masking drastically reduced the number of voxel-by-voxel statistical comparisons, and a threshold of P<0.001 (cluster-corrected at P<0.05) was considered to be statistically significant.1
At baseline, 18F-FDG PET revealed slightly asymmetrical hypermetabolism bilaterally in the putamen and cerebellar vermis (Figure S1), while at follow-up one year after DBS the extent of FDG hypermetabolism in the putamen decreased bilaterally and the extent of FDG hypermetabolism increased in the cerebellum and cerebellar vermis.
Figure S1 Comparison of 18F-FDG PET imaging before and after deep brain stimulation in patient’s right subthalamic nucleus.
Wang J, Ma Y, Huang Z, et al. Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson’s disease. J Neurol. 2010;257(1):72–78.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]